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Expression of parathyroid hormone/parathyroid
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and diseased bladder detrusor muscles: a
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Abstract
Background: To investigate the expression of parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor 1
(PTH1R) in clinical specimens of normal and diseased bladders. PTHrP is a unique stretch-induced endogenous
detrusor relaxant that functions via PTH1R. We hypothesized that suppression of this axis could be involved in the
pathogenesis of bladder disease.
Methods: PTH1R expression in clinical samples was examined by immunohistochemistry. Normal kidney tissue from
a patient with renal cancer and bladder specimens from patients undergoing ureteral reimplantation for
vesicoureteral reflux or partial cystectomy for urachal cyst were examined as normal control organs. These were
compared with 13 diseased bladder specimens from patients undergoing bladder augmentation. The
augmentation patients ranged from 8 to 31 years old (median 15 years), including 9 males and 4 females. Seven
patients had spinal disorders, 3 had posterior urethral valves and 3 non-neurogenic neurogenic bladders (Hinman
syndrome).
Results: Renal tubules, detrusor muscle and blood vessels in normal control bladders stained positive for PTH1R.
According to preoperative urodynamic studies of augmentation patients, the median percent bladder capacity
compared with the age-standard was 43.6% (range 1.5–86.6%), median intravesical pressure at maximal capacity
was 30 cmH2O (range 10–107 cmH2O), and median compliance was 3.93 ml/cmH2O (range 0.05–30.3 ml/cmH2O).
Detrusor overactivity was observed in five cases (38.5%). All augmented bladders showed negative stainings in
PTH1R expression in the detrusor tissue, but positive staining of blood vessels in majority of the cases.
Conclusions: Downregulation of PTH1R may be involved in the pathogenesis of human end-stage bladder disease
requiring augmentation.
Keywords: Parathyroid hormone-related peptide, Parathyroid hormone 1 receptor, Bladder compliance,
Smooth muscle
Background
Relaxation of the detrusor muscle is a fundamental re-
quirement for normal bladder storage function. Severe
failure of this relaxation mechanism causes upper urinary
tract deterioration as a result of abnormal elevation of
intravesical pressure [1]. Such extreme pathology is
termed low-compliance bladder, and is typically seen in
paediatric cases with congenital spinal disorders, posterior
urethral valves, and also in rare forms of severe non-
neurogenic neurogenic bladder (Hinman syndrome). The
primary goal in treating such patients is to prevent urinary
tract damage by maintaining low-pressure storage and
effective bladder evacuation [2]. This is usually achieved
through medical therapy using antimuscarinic drugs
combined with clean intermittent catheterization. However,
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if these conservative therapies fail, bladder augmentation
using the digestive tract is indicated, though such surgery
may lead to various long-term complications, including
metabolic acidosis, bowel dysfunction, rupture, and risk of
secondary malignancies [3,4]. However, despite these
clinical problems, the molecular mechanisms underlying
low-compliance end-stage bladder disease have not yet
been thoroughly investigated [4].
Parathyroid hormone-related peptide (PTHrP) was ori-
ginally identified as a cause of hypercalcemia in paraneo-
plastic syndrome, [5] and has since been found to be
expressed in most systemic tissues, with diverse physio-
logical roles [6,7]. We previously reported that PTHrP
acted as a stretch-induced endogenous relaxant of detrusor
muscle [8]. PTHrP functions via the PTH/PTHrP receptor
1 (PTH1R), which is expressed in detrusor muscle but not
in urothelium. In rat experiments, PTHrP peptide potently
suppressed spontaneous contraction of detrusor muscle
strips, and intravenous administration of PTHrP peptide in-
creased bladder compliance [8]. These results suggest that
endogenous PTHrP may inhibit the abnormal decrease in
bladder compliance by bladder distention. We hypothesized
that PTH1R should also be expressed in human bladder de-
trusor muscle, and that suppression of this axis could be in-
volved in the pathogenesis of end-stage low-compliance
bladder.
In this study, we therefore investigated the expression of
PTH1R in clinical specimens from patients with normally
functioning bladder and those undergoing bladder augmen-
tations, to explore the involvement of the PTHrP-PTH1R
axis in normal and diseased bladder detrusor muscle.
Methods
Clinical specimens
This study was authorized by the Institutional Review
Board of Kyoto University (G279) and Tokyo Women’s
Medical University (2089), and written informed con-
sents for participation in the study were obtained from
participants or parents. Normal kidney tissue, as a
positive control of PTH1R, was obtained from a neph-
rectomy specimen from a patient with renal cell carcin-
oma without paraneoplastic hypercalcemia, and was
used as a positive control for the staining procedure.
Bladder specimens were obtained from the bladder
dome by sagittal section in following patients. In total,
3 normal control bladder tissues were obtained during
cystotomy for ureteral reimplantation for vesicouret-
eral reflux in two patients, and partial cystectomy for
urachal cyst in one patient, who all underwent surgery
at the Department of Urology, Kyoto University Hospital.
These three patients had no symptoms of abnormal
bladder storage or emptying. The clinical backgrounds
of the control patients are summarized in Table 1. Data
are expressed as mean ± S.D.
In total, 13 diseased bladder tissues were obtained from
patients who underwent bladder augmentation at the De-
partment of Urology, Tokyo Women’s Medical University.
The clinical backgrounds of the patients are summarized
in Table 2. The median age of the patients was 15 years
(range 8–31 years, mean 17.8 ± 8.8 years), and included 9
males and 4 females. Seven patients had spinal disorders,
three had posterior urethral valves and three had Hinman
syndrome. All the patients underwent preoperative urody-
namic studies combined with cystography. Bladder aug-
mentation was indicated for low-compliance bladder and/
or incontinence, despite aggressive anti-cholinergic regi-
mens. The bladder capacity was presented as the percent-
age of the reported age-standard capacity for Japanese
children, calculated by the formula 25 × (age in years + 2)
for patients younger than 12 years, and 350 ml was de-
fined as 100% for patients older than 12 years [9].
Immunohistochemistry
The specimens were fixed in formalin and paraffin-
embedded. Sections were mounted on glass slides and
used for immunohistochemical detection of PTH1R. In-
cubation and washing procedures were carried out at
room temperature, unless otherwise specified. Deparaffi-
nization and antigen retrieval were carried out in a
microwave, as described previously, [10] and endogen-
ous peroxidase activity was then blocked with 0.3%
H2O2 in methyl alcohol for 30 min. The glass slides were
washed six times in phosphate-buffered saline (PBS) for
5 min each, and mounted with 1% horse normal serum
in PBS for 30 min for pre-blocking. Primary antibody
against PTH1R (3D1.1, Santa Cruz Biotechnology,
Dallas, TX, USA; 1:100) was then applied overnight at
4°C, followed by incubation with biotinylated horse anti-
mouse serum (second antibody) (ABC-Elite, Vector La-
boratories, Burlingame, CA, USA) diluted 1:300 in PBS
for 40 min, followed by six washes in PBS (5 min each).
Avidin-biotin-peroxidase complex (ABC-Elite, Vector
Laboratories, Burlingame, CA) was applied for 50 min at
a dilution of 1:100 in bovine serum albumin. After wash-
ing six times in PBS (5 min each), a coloring reaction
was carried out using diaminobenzidine, with a uniform
reaction time for all specimens. Nuclei were counter-
stained with haematoxylin. PTH1R protein-expression
intensity was classified as negative or positive by two in-
dependent examiners, with reference to renal tubules as
a positive immunostaining control.
Results
Immunostaining study with PTH1R of a kidney and
normal control bladders
In the kidney specimen, the tubules stained positive for
PTH1R, in contrast to the glomeruli, which stained faint,
as reported previously (Figure 1A) [11]. In the normal
Nishikawa et al. BMC Urology 2015, 15:2 Page 2 of 6
http://www.biomedcentral.com/1471-2490/15/2
control bladder specimens, both the detrusor tissue and
blood vessel stained positive for PTH1R. Staining in the
detrusor tissue was mainly observed in the cytosol
(Figure 1B).
Preoperative urodynamic study
Preoperative urodynamic study revealed that the blad-
ders in all patients undergoing bladder augmentation had
deteriorated storage function. The median bladder cap-
acity was 146 ml (range 5–303 ml, mean 153.6 ± 84.0 ml),
median percent capacity of age-standard was 43.6% (range
1.5–86.6%, mean 46.9 ± 23.2%), median intravesical pres-
sure at maximal capacity was 30 cmH2O (range 10–107
cmH2O, mean 38.8 ± 23.3cmH2O), and the median com-
pliance was 3.93 ml/cmH2O (range 0.05–30.3 ml/cmH2O,
mean 6.6 ± 7.8 ml/cmH2O). Detrusor overactivities were
noted in five patients and vesicoureteral reflux in eight pa-
tients (Table 2).
Immunostaining study with PTH1R of low compliance
bladder
All of the bladder-augmentation specimens showed
negative PTH1R staining in detrusor smooth muscle
cells in the bladder wall, in contrast to the positive stain-
ing seen in normal control bladder specimen. However,
blood vessels stained positive for PTH1R in seven out of
13 augmentation cases (53.8%), indicating that the nega-
tive staining was not the result of a technical failure, but
rather reflected downregulation of PTH1R expression in
these bladders (Figure 2).
Discussion
This paper demonstrated the expression of PTH1R in
normal bladder tissue and its downregulation in end-
stage low-compliance bladders requiring augmentation.
Combined with the potent relaxant effect of PTHrP pep-
tide in rat bladder reported in our previous study, [8]
these findings suggest the functional involvement of this
axis in normal human bladder physiology, and its loss in
severely diseased bladders with decreased compliance.
The relaxant effect of PTHrP in the bladder has been
reported previously [12,13] Yamamoto et al. focused on
stretch-induced upregulation of PTHrP in the bladder
in vivo, [12] which effect was replicated in cultured
smooth muscle cells under stretch by Steers et al [13].
However, PTHrP showed only modest suppression of
carbachol-induced contraction of bladder strips in those
Table 1 Clinical background and immunostaining result






Normal Kidney Renal Cell
Carcinoma
M 54 N/A +
Normal
bladder-1
Urachal cyst F 57 + +
Normal bladder-2 Vesicoureteral
reflux





F 12 + +
IHC, immunohistochemistry.
Table 2 Clinical background and staining results of the diseased bladder

















Myelomeningocele-1 M 14 60 17.1 40 1.5 - - Incontinent - -
Myelomeningocele-2 F 15 117 33.4 53 2.21 - + >60 - +
Myelomeningocele-3 M 20 250 71.4 24 10.4 - - 25 - -
Myelomeningocele-4 F 27 147 42.0 30 4.9 - + 22.5 - -
Myelomeningocele-5 F 29 212 60.6 23 9.22 + + 25 - -
Sacral agenesis-1 M 30 146 41.7 30 4.87 - + NA - +
Sacral agenesis-2 F 31 266 76.0 30 8.87 - + NA - -
Posterior urethral valve-1 M 8 109 43.6 47 2.32 - - >40 - +
Posterior urethral valve-2 M 10 147 49.0 40 3.68 - + >40 - +
Posterior urethral valve-3 M 11 5 1.5 107 0.05 + - NA - -
Hinman syndrome-1 M 8 118 47.2 30 3.93 + + >60 - +
Hinman syndrome-2 M 10 117 39.0 40 2.93 + - Incontinent - +
Hinman syndrome-3 M 18 303 86.6 10 30.3 + + NA - +
DO, detrusor overactivity; VUR, vesicouteral reflux; IHC, immunohistochemistry.
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Figure 1 PTH1R immunohistochemical staining of normal kidney tissue and normal control bladder detrusor tissues. (A) Renal tubules
were positively stained, in contrast to faint staining in glomeruli. (B) Cytoplasm of normal bladder detrusor muscle cells and blood vessels
showed positive staining with PTH1R antibody. Scale bar: 100 μm.
Figure 2 PTH1R immunohistochemical staining of diseased bladder detrusor tissues. All diseased bladder detrusor tissues showed negative
staining with PTH1R antibody, regardless of the underlying diseases, but positive staining of blood vessels was retained in many specimens. Scale
bar: 100 μm.
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studies, leaving the physiological relevance of this obser-
vation unanswered. In contrast, our recent study in rats
showed a potent relaxant effect of PTHrP in suppressing
the spontaneous contraction of detrusor strips, and thus
increasing bladder compliance in vivo [8]. Our study also
demonstrated that PTH1R was expressed primarily in
the muscle layer, and not in the urothelial layer. As a lo-
gical extension of this previous study, we investigated
the expression of PTH1R in the human bladder, and this
report supplements and advances the previous study, by
investigating the clinical relevance of this axis utilizing
human samples.
Detrusor muscle tissues in normal control bladders
stained positive for PTH1R, especially in the cytosol.
This result seems to contradict the fact that PTH1R is a
membrane-anchored G protein-coupled receptor, [14]
allowing binding of PTHrP at the membrane surface.
However, PTH1R translocation from the plasma mem-
brane into the cytosol after incubation with the PTH1R
agonist, PTH (1–34), and positive staining in the cytosol
was also seen in other organs such as acinar cells of the
prostate gland, cell clusters within the adrenal cortex
and cells of the epithelial hair sheath [11].
In sharp contrast, the detrusor muscle in augmented
bladders showed negative staining for PTH1R. This lack
of staining did not indicate a technical failure, given that
blood vessels stained positively in seven out of 13 (53.8%)
cases. The negative staining of vessels in the remaining six
cases may have been associated with deterioration of the
vessels themselves, or technical failure caused by different
fixation conditions. If PTH1R is downregulated in these
bladders, they may not be able to respond to endogenous
PTHrP, which could function as a protective relaxant
against excessive distention. Downregulation of PTH1R is
thus consistent with low bladder compliance.
In regard of the functional effect in PTHrP-PTH1R
axis in the bladder, not only the receptor PTH1R, but
expression level of the ligand PTHrP, in normal and dis-
eased bladder is also of a great interest. Perez-Martinez
et al. reported about PTHrP immunostaining in rabbit
bladder outlet obstruction model [15]. However, we did
not succeed in visualizing PTHrP signal in paraffin-
embedded human bladder, nor in rat bladder under va-
rious fixation conditions. Therefore we did not focus on
expression of PTHrP in this study.
Further physiological experiments would have been ideal
to confirm these speculations, demonstrating the unre-
sponsiveness of diseased bladder strips to PTHrP peptide.
Similarly, it may be of interest whether the difference in
expression level of PTH1R may be attributed to altered
production, degradation, release, or removal. Unfortu-
nately, it was practically impossible to obtain materials
at the separate time of surgery and subsequently perform
physiological experiment or obtain enough materials for
various biochemical assays. Such mechanistic part should
be better studied in experimental model system such as
cultured cells and animals, as we did in our previous
report, rather than in clinical samples. Therefore it is ine-
vitable limitation of the present study design that it is unidi-
mensional, but supplemented by our previous mechanistic
study, it addresses more direct clinical relevance.
Clinical translation of the results of this study may not
be straightforward. If downregulation of PTH1R is a fea-
ture of low-compliance bladders, it would be difficult to
use this axis as a target for treatment. However, it is
possible that bladders still positive for PTH1R may re-
tain the ability to relax against excessive distention,
while downregulation of PTH1R could be a marker for
unresponsiveness to conservative therapy, indicating the
need for bladder augmentation. In addition, the PTHrP-
PTH1R axis could be a target for treating milder damage
in bladders retaining PTH1R expression, including over-
active bladder, which affects a far larger percentage of the
population than severely diseased bladder. Unfortunately,
currently-available PTH1R agonists have systemic side
effects that preclude their use for bladder diseases, and
bladder-specific derivatives are awaited to allow the
clinical translation of the PTHrP-PTH1R axis for treat-
ing bladder diseases.
Conclusions
In conclusion, we demonstrated PTH1R expression in the
smooth muscle in normal bladders, in contrast to negative
expression in muscle from severely diseased bladders.
Suppression of the PTHrP-PTH1R axis may therefore be
involved in bladder pathophysiology.
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